US ITC Withdraws Import Ban Order on Daewoong Pharmaceutical's Nabota
ITC Final Ruling Invalidation Request 'Dismissed'
[Asia Economy Reporter Kim Ji-hee] Medytox announced on the 4th that the import ban order on Daewoong Pharmaceutical's botulinum toxin 'Nabota' (U.S. name: Jeuveau), which was filed with the U.S. International Trade Commission (ITC) following a tripartite agreement with Allergan and Evolus, has been withdrawn. Accordingly, Evolus can continue selling Nabota in the United States.
Daewoong Pharmaceutical submitted its consent to the withdrawal of the order on April 4th, as requested by the parties involved in the agreement. At the same time, Daewoong filed a petition to nullify the ITC's final ruling that found Daewoong had infringed Medytox's manufacturing process trade secrets. However, while the ITC approved the withdrawal request from the three parties, it dismissed Daewoong's petition to invalidate the final ruling.
A Medytox official stated, "Daewoong's agreement to the withdrawal request from the three parties without objection essentially means they have acknowledged the ITC's final ruling, which explicitly stated their allegations of theft and false claims." The official added, "Daewoong's claim that they will correct the ruling through an appeal, while simultaneously arguing to the ITC that an appeal is meaningless and petitioning to invalidate the final ruling, denies the U.S. ITC's judgment after a thorough investigation." Medytox plans to use the evidence related to the ITC's final ruling in domestic civil litigation as well.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "Trump and Netanyahu Hold Talks on Iran War...Possibility of Resuming Military Action"
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
Meanwhile, Medytox, together with Allergan, filed a lawsuit with the ITC in February 2019 against Daewoong Pharmaceutical and Evolus for the theft of Medytox's strains and manufacturing processes. Two years later, at the end of last year, the ITC issued a final ruling that Daewoong had stolen Medytox's manufacturing process, and following approval by the U.S. President, a 21-month import and sales ban on Daewoong's Nabota in the United States was enforced.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.